Kazia Therapeutics Limited
KZIA
$13.25
$3.1931.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.50K | 13.20K | -- | -- | 760.50K |
| Total Other Revenue | 565.20K | 553.50K | 7.30K | 7.50K | 57.00K |
| Total Revenue | 578.70K | 566.70K | 7.30K | 7.50K | 817.50K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 578.70K | 566.70K | 7.30K | 7.50K | 817.50K |
| SG&A Expenses | 1.16M | 1.13M | 1.66M | 1.71M | 2.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.13M | 2.09M | 3.06M | 3.15M | 7.27M |
| Operating Income | -1.55M | -1.52M | -3.05M | -3.14M | -6.45M |
| Income Before Tax | -3.80M | -3.72M | -3.45M | -3.55M | -5.96M |
| Income Tax Expenses | -515.80K | -505.10K | -44.20K | -45.40K | -44.60K |
| Earnings from Continuing Operations | -3.28M | -3.21M | -3.41M | -3.50M | -5.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.28M | -3.21M | -3.41M | -3.50M | -5.92M |
| EBIT | -1.55M | -1.52M | -3.05M | -3.14M | -6.45M |
| EBITDA | -1.40M | -1.33M | -2.75M | -2.83M | -6.14M |
| EPS Basic | -1.22K | -1.20K | -2.00K | -2.06K | -5.14K |
| Normalized Basic EPS | -0.79 | -0.77 | -2.72 | -2.79 | -6.58 |
| EPS Diluted | -1.22K | -1.20K | -2.00K | -2.06K | -5.14K |
| Normalized Diluted EPS | -0.79 | -0.77 | -2.72 | -2.79 | -6.58 |
| Average Basic Shares Outstanding | 1.34M | 1.34M | 850.30K | 850.30K | 575.10K |
| Average Diluted Shares Outstanding | 2.60K | 2.60K | 1.70K | 1.70K | 1.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |